诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688428 诺诚健华

已收盘 05-17 15:00:00

{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":8.24,"timestamp":1715929200000,"preClose":8.09,"halted":0,"volume":2844770,"delay":0,"floatShares":256999999,"shares":1763000000,"eps":-0.432,"marketStatus":"已收盘","marketStatusCode":5,"change":0.15,"latestTime":"05-17 15:00:00","open":8.17,"high":8.26,"low":8.05,"amount":23254400,"amplitude":0.026,"askPrice":8.25,"askSize":124,"bidPrice":8.24,"bidSize":633,"shortable":0,"etf":0,"ttmEps":-0.432,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716168600000},"adr":0,"adjPreClose":8.09,"symbolType":"stock_kcb","openAndCloseTimeList":[[1715909400000,1715916600000],[1715922000000,1715929200000]],"highLimit":8.9,"lowLimit":7.28,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1762582452,"pbRate":2.07,"roa":"--","roe":"--","epsLYR":-0.37,"committee":-0.177878,"marketValue":14524000000,"floatMarketCap":2115000000,"peRate":-19.074074,"changeRate":0.0185,"turnoverRate":0.0111,"status":0,"afterMarket":{"amount":0,"volume":0,"close":8.24,"buyVolume":0,"sellVolume":0,"time":1715931239505,"indexStatus":"已收盘 05-17 15:30:00","preClose":8.09}},"requestUrl":"/m/hq/s/688428/wiki","defaultTab":"wiki","newsList":[{"id":"2436795019","title":"诺诚健华(09969)股价上升5.01%，现价港币$5.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2436795019","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2436795019?lang=zh_cn&edition=full","pubTime":"2024-05-17 13:05","pubTimestamp":1715922300,"startTime":"0","endTime":"0","summary":"[上升股]诺诚健华(09969) 股价在下午01:05比前收市价上升5.01%，现股价为港币$5.24。至目前为止，今日最高价为$5.24，而最低价为$4.99。总成交量为570.6万股，总成交金额为港币$2.944千万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2405171991/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2436064953","title":"诺诚健华现涨超3% ICP-488治疗银屑病II期临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2436064953","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2436064953?lang=zh_cn&edition=full","pubTime":"2024-05-17 10:18","pubTimestamp":1715912280,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　诺诚健华（09969）早盘上涨3.41%，现报5.16港元，成交额1198.04万港元。\n　　5月16日，诺诚健华宣布，公司自主研发的TYK2（酪氨酸激酶2）JH2变构抑制剂ICP-488治疗银屑病的II期临床试验完成患者入组。ICP-488在治疗银屑病患者的I期研究中展示了良好的有效性和安全性。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-05-17/doc-inavnxhm9076340.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-05-17/doc-inavnxhm9076340.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2436533049","title":"港股异动 | 诺诚健华(09969)现涨超4% ICP-488治疗银屑病II期临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2436533049","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2436533049?lang=zh_cn&edition=full","pubTime":"2024-05-17 10:09","pubTimestamp":1715911791,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华现涨超4%，截至发稿，涨4.41%，报5.21港元，成交额1139.44万港元。消息面上，5月16日，诺诚健华宣布，公司自主研发的TYK2JH2变构抑制剂ICP-488治疗银屑病的II期临床试验完成患者入组。ICP-488在治疗银屑病患者的I期研究中展示了良好的有效性和安全性。该行表示，诺诚健华首季现金余额达82亿元人民币，为管线开发等提供灵活性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1122407.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435362880","title":"高盛：予诺诚健华(09969)“买入”评级 目标价升至8.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435362880","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2435362880?lang=zh_cn&edition=full","pubTime":"2024-05-16 15:28","pubTimestamp":1715844518,"startTime":"0","endTime":"0","summary":"高盛将诺诚健华(09969)今年全年销售预测由8.17亿元人民币上调至8.39亿元人民币。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20240516/20240516152851_26780.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240516/20240516152851_26780.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121939.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435868643","title":"《大行》高盛微升诺诚健华(09969.HK)目标价至8.6元  评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2435868643","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2435868643?lang=zh_cn&edition=full","pubTime":"2024-05-16 12:00","pubTimestamp":1715832000,"startTime":"0","endTime":"0","summary":"高盛发表报告指出，诺诚健华首季销售疲弱，其奥布替尼销售1.65亿元人民币，按年增长9%，按季则跌13%，复苏速度慢于预期，因为治疗复发/难治性边缘区淋巴瘤新适应症新获纳入国家医保目录，料销量提升需时。该行提及，诺诚健华首季现金余额达82亿元人民币，为管线开发等提供灵活性。该行将诺诚健华今年全年销售预测由8.17亿元人民币上调至8.39亿元人民币，并下调2024至2026年各年盈测，目标价由8.58元微升至8.6元，评级“买入”。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200917152907442_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200917152907442_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1349873/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2435689513","title":"诺诚健华跌4.43% 2022年上市募29亿2023年亏6.3亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2435689513","media":"中国经济网","top":-1,"share":"https://www.laohu8.com/m/news/2435689513?lang=zh_cn&edition=full","pubTime":"2024-05-15 16:14","pubTimestamp":1715760840,"startTime":"0","endTime":"0","summary":"　　诺诚健华于2022年9月21日在上交所科创板上市，公开发行264,648,217股，发行价格为11.03元/股，上市首日即破发收报9.33元，下跌15.41%。　　诺诚健华首次公开发行股票募集资金总额为291,906.98万元，募集资金净额为277,881.56万元。诺诚健华首次公开发行股票的发行费用总额为14,025.42万元，其中承销费用及保荐费用11,216.74万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-05-15/doc-inavhzym3153690.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-05-15/doc-inavhzym3153690.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435044599","title":"核心产品一季度销售超1.6亿 难挽诺诚健华继续亏损局面","url":"https://stock-news.laohu8.com/highlight/detail?id=2435044599","media":"新京报网","top":-1,"share":"https://www.laohu8.com/m/news/2435044599?lang=zh_cn&edition=full","pubTime":"2024-05-14 19:03","pubTimestamp":1715684580,"startTime":"0","endTime":"0","summary":"5月14日发布的一季报显示，诺诚健华报告期内实现营收1.66亿元，同比下降12.44%，亏损规模为1.42亿元。同多家创新型生物医药公司一样，诺诚健华一直处于亏损中。不过，截至今年一季度末，诺诚健华持有货币资金约82亿元。今年一季度，奥布替尼实现销售收入1.64亿元，同比增长9%，照此计算，奥布替尼凭一己之力几乎撑起了诺诚健华同时期99%的营收。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405141907287a59d26d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405141907287a59d26d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435756469","title":"诺诚健华一季度净亏损1.42亿元 亏损同比扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2435756469","media":"经济参考网","top":-1,"share":"https://www.laohu8.com/m/news/2435756469?lang=zh_cn&edition=full","pubTime":"2024-05-14 16:44","pubTimestamp":1715676283,"startTime":"0","endTime":"0","summary":"诺诚健华5月13日晚间发布公告称，公司2024年第一季度实现营业收入1.66亿元，同比下降12.44%；实现归属于上市公司股东的净利润-1.42亿元，实现扣非净利润-1.34亿元，亏损同比扩大；此外，公司经营活动产生的现金流量净额为-0.84亿元。其中，作为公司的核心产品，奥布替尼(宜诺凯)2024年第一季度实现销售收入1.64亿元，同比增长9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405141646138767a9bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405141646138767a9bb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435537219","title":"《大行》瑞银升诺诚健华(09969.HK)目标价至7.6元  首季业绩逊预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2435537219","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2435537219?lang=zh_cn&edition=full","pubTime":"2024-05-14 10:59","pubTimestamp":1715655540,"startTime":"0","endTime":"0","summary":"瑞银发表报告指出，诺诚健华首季收入按年跌12.4%至1.66亿元人民币，低过市场预期的1.82亿元人民币；净亏损扩大10.4倍至1.42亿元人民币，亦逊预期，主要由于财务收入减少。该行将诺诚健华今明两年收入预测各上调12.3%及10.9%，销售费用率分别上调10及3个百分点，令每股亏损由原预期的36及33分人民币，扩大至44及39分人民币。对其目标价由7元上调至7.6元，维持“买入”评级。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200917152905880_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200917152905880_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1349415/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2435308342","title":"《业绩》诺诚健华(09969.HK)第一季亏损扩至1.42亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2435308342","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2435308342?lang=zh_cn&edition=full","pubTime":"2024-05-14 00:40","pubTimestamp":1715618400,"startTime":"0","endTime":"0","summary":"诺诚健华(09969.HK) 公布3月止第一季度报告，按中国会计准则，实现营业收入1.66亿人民币(下同)，按年下降12.4%。亏损由上年同期1,241万元，扩至1.42亿元，每股亏损8分。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-05-13 16:25。)过往派息公布日期派息事项派息内容2024/03/28末期业绩无派息2023/11/13第三季业绩无派息2023/08/29中期业绩无派息2023/05/09第一季业绩无派息 AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200917152907442_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200917152907442_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1349270/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2435326643","title":"诺诚健华(688428.SH)发布一季度业绩，净亏损1.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435326643","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435326643?lang=zh_cn&edition=full","pubTime":"2024-05-13 19:16","pubTimestamp":1715598987,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(688428.SH)发布2024年第一季度报告，公司营业收入1.66亿元，同比下降12.44%;归属于上市公司股东的净亏损1.42亿元;归属于上市公司股东的扣除非经常性损益的净亏损1.34亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120649.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435263293","title":"诺诚健华(09969)一季度归母净亏损1.42亿元，同比扩大1047.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435263293","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2435263293?lang=zh_cn&edition=full","pubTime":"2024-05-13 19:14","pubTimestamp":1715598878,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布2024年第一季度季度报告，营业收入1.66亿元(人民币，下同)，同比下降12.44%;归属于上市公司股东的净亏损1.42亿元，同比扩大1047.8%;基本每股亏损0.08元。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120647.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433126474","title":"诺诚健华-U05月06日主力资金流出95万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2433126474","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433126474?lang=zh_cn&edition=full","pubTime":"2024-05-06 15:19","pubTimestamp":1714979942,"startTime":"0","endTime":"0","summary":"05月06日, 诺诚健华-U股价涨3.46%，报收8.96元，成交金额3900万元，换手率1.70%，振幅3.58%，量比1.10。诺诚健华-U今日主力资金净流出95万元，连续3日净流出，上一交易日主力净流出214万元，今日环比减少55.61%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为43.48%，平均跌幅为1.52%。该股近5个交易日上涨9.80%，主力资金累计净流出964万元；近20日主力资金累计净流出6398万元，其中净流出天数为16日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050615342587d78dcf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050615342587d78dcf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433460709","title":"诺诚健华(09969)下跌5.05%，报5.08元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433460709","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2433460709?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:38","pubTimestamp":1714963106,"startTime":"0","endTime":"0","summary":"5月6日，诺诚健华(09969)盘中下跌5.05%，截至10:38，报5.08元/股，成交1470.35万元。诺诚健华医药有限公司是一家拥有一体化生物医药平台的领先企业，主要从事研发治疗癌症和自身免疫性疾病的创新药物。公司具备强大的内部研发能力和世界级管理团队，同时拥有均衡的管线组合和针对经过验证或新颖生物通路的候选药物。截至2023年年报，诺诚健华营业总收入7.39亿元、净利润-6.31亿元。5月13日，诺诚健华将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/06103840523819.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433460724","title":"诺诚健华盘中异动 股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433460724","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433460724?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:34","pubTimestamp":1714962899,"startTime":"0","endTime":"0","summary":"2024年05月06日早盘10时34分，诺诚健华股票出现波动，股价急速下挫5.05%。截至发稿，该股报5.080港元/股，成交量258.9万股，换手率0.17%，振幅3.74%。资金方面，该股资金流入485.082万港元，流出670.773万港元。诺诚健华股票所在的生物技术行业中，整体涨幅为1.41%。诺诚健华公司简介：诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061035007925eb96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061035007925eb96&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433691934","title":"南向资金4月30日净卖出诺诚健华105.60万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2433691934","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433691934?lang=zh_cn&edition=full","pubTime":"2024-05-06 09:31","pubTimestamp":1714959071,"startTime":"0","endTime":"0","summary":"4月30日，南向资金减持诺诚健华105.60万股连续5日减持。截止当日收盘，港股通共持有诺诚健华21966.89万股，占流通股12.45%。诺诚健华近5个交易日上涨9.72%，港股通累计减持389.40万股；近20个交易日下跌0.43%，港股通累计增持131.90万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050609423687d64c83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050609423687d64c83&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432644950","title":"诺诚健华(09969)股价显著上升14.471%，现价港币$5.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2432644950","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432644950?lang=zh_cn&edition=full","pubTime":"2024-05-02 15:09","pubTimestamp":1714633740,"startTime":"0","endTime":"0","summary":"[上升股]诺诚健华(09969) 股价在下午03:09比前收市价显著上升14.471%，现股价为港币$5.3。至目前为止，今日最高价为$5.3，而最低价为$4.56。总成交量为170.472万股，总成交金额为港币$865.942万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2405024725/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2432769493","title":"诺诚健华盘中异动 早盘快速上涨5.40%报4.880港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432769493","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432769493?lang=zh_cn&edition=full","pubTime":"2024-05-02 10:44","pubTimestamp":1714617848,"startTime":"0","endTime":"0","summary":"2024年05月02日早盘10时44分，诺诚健华股票出现异动，股价大幅上涨5.40%。截至发稿，该股报4.880港元/股，成交量27.4721万股，换手率0.02%，振幅6.91%。诺诚健华股票所在的生物技术行业中，整体涨幅为0.56%。消息层面，截至10时44分，《太平洋：给予诺诚健华买入评级，目标价位16.1元》资讯为影响诺诚健华的重要信息。首次覆盖给予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240502104409861eaa27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240502104409861eaa27&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-09-21","address":"OgierGlobal(Cayman)Limited,89NexusWay,CamanaBay,GrandCayman,KY1-9009,CaymanIslands","stockEarnings":[{"period":"1week","weight":-0.071},{"period":"1month","weight":0.03},{"period":"3month","weight":-0.0855},{"period":"6month","weight":-0.2623},{"period":"1year","weight":-0.3715},{"period":"ytd","weight":-0.2835}],"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"0万元","compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.0326},{"period":"1year","weight":-0.0435},{"period":"ytd","weight":0.0602}],"survey":"　　诺诚健华医药有限公司的主营业务为创新药的研发、生产及商业化。主要产品为奥布替尼、ICP-192、ICP-723、ICP-332、ICP-189、ICP-490、Tafasitamab、ICP-105、ICP-033、ICP-488、ICP-248、ICP-B03、ICP-915、ICP-B02等。公司获得奖项为中国技术创业协会科技创新贡献奖、北京市“专精特新”中小企业、中国新经济企业500强等。","serverTime":1716082107785,"listedPrice":11.03,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}